Docetaxel/platinum combinations are efficacious in treatment of NSCLC


A regimen of docetaxel and cisplatin offers better survival and response rates than a combination of vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer, according to a phase 3 study published in the online version of the Journal of Clinical Oncology. In addition, the findings demonstrated that docetaxel is as effective as vinorelbine/cisplatin when combined with another platinum, carboplatin.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.